Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase 4 2Phase 2 2Phase 1/2 2Phase 1 1

Status

Completed 3

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 3Lymphoid 3Myeloid 1

Conditions

Leukemia, Myeloid, Acute 263Leukemia 190Leukemia, Lymphocytic, Chronic, B-Cell 166Precursor Cell Lymphoblastic Leukemia-Lymphoma 154Myelodysplastic Syndromes 83Lymphoma 79Leukemia, Myelogenous, Chronic, BCR-ABL Positive 71Hematologic Neoplasms 62Lymphoma, Non-Hodgkin 61Lymphoma, Follicular 54Leukemia, Myeloid, Chronic-Phase 53Burkitt Lymphoma 51Lymphoma, Large B-Cell, Diffuse 47Lymphoma, B-Cell, Marginal Zone 45Lymphoma, Mantle-Cell 44Multiple Myeloma 42Leukemia, Myelomonocytic, Chronic 41Hodgkin Disease 41Myeloproliferative Disorders 38Neoplasms 37Lymphoma, Large-Cell, Immunoblastic 37Recurrence 31Leukemia, Myeloid, Accelerated Phase 28Congenital Abnormalities 27Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 26Leukemia, Biphenotypic, Acute 26Lymphoma, T-Cell, Cutaneous 25Blast Crisis 24Waldenstrom Macroglobulinemia 23Leukemia, Myelomonocytic, Acute 23

Interventions

Allopurinol 2venetoclax 1rasburicase 1obinutuzumab 1Urate Oxidase 1Febuxostat 1Bendamustine Hydrochloride 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 3 × Tumor Lysis Syndrome × Other hematologic neoplasm × Clear all
NCT03406156 2024-08-06

A Study in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Subjects, Excluding Those With the 17p Deletion, to Evaluate Debulking Regimens Prior to Initiating Venetoclax Combination Therapy

AbbVie

Phase 3 Completed
120 enrolled 14 charts
LymphoidOther hematologic neoplasm

Chromosome 17 deletion, Neoplasms, Tumor Lysis Syndrome, Leukemia, Lymphocytic, Chronic, B-Cell

NCT01724528 2014-11-03

FLORENCE

Menarini Group

Phase 3 Completed
346 enrolled 16 charts
LymphoidOther hematologic neoplasm

Leukemia, Lymphoma, Tumor Lysis Syndrome

NCT00230178 2010-01-12

Rasburicase Versus Allopurinol in Tumor Patients at Risk for Hyperuricemia and Tumor Lysis Syndrome

Sanofi

Phase 3 Completed
280 enrolled 10 charts
LymphoidMyeloidOther hematologic neoplasm

Leukemia, Lymphoma, Myelodysplastic Syndromes, Neoplasms, Tumor Lysis Syndrome, Hyperuricemia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡